Beta Bionics (BBNX) CCO Mark Hopman Sells 5,327 Shares

What Happened
Mark Hopman, Chief Commercial Officer of Beta Bionics (BBNX), sold 5,327 shares on 2026-09-02 in an open‑market/private sale (Form 4 code S). The weighted average sale price was $19.1131 (range $18.89–$19.545), producing total proceeds of about $101,815. The filing notes the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

Key Details

• Transaction date: 2026-09-02; Form 4 filed: 2026-09-03 (timely; Form 4 due within 2 business days).
• Transaction type: Sale (S) — open market or private sale.
• Price: weighted average $19.1131; price range $18.89 to $19.545 (footnote F2: detailed per-price breakdown available on request).
• Proceeds: approximately $101,815.
• Footnote F1: sale was to satisfy tax withholding on RSU vesting.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• No indication in the provided data that this was a 10% owner transaction or an options exercise.

Context
Sales to cover tax withholding after RSU vesting are routine and commonly do not signal a change in an insider’s view of the company. This transaction was a disposition (not a purchase) and appears to be administrative in nature per the filing.